Title:
|
UARK 2006-15: A Phase III Randomized Study of Tandem Transplants With or Without Bortezomib (Velcade) and thalidomide (thalomid) to Evaluate Its Effect on Response Rate and Durabilityof Response in Multiple Myeloma Patients
|
| Sponsor: |
University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy
|
| PI: |
Guido Tricot, M.D., Ph.D.
|
| Phase: |
III
|
| Purpose: |
To find out if adding three drugs, bortezomib, thalidomide, and examethasone (VTD) to the high dose chemotherapy regimen immediately before transplant (DPACE/Melphalan) will result in better myeloma response and longer survival of myeloma subjects compared to treatment with high-dose chemotherapy not containing these drugs. To find out what the side effects will be with both transplant regimens.
|
| Eligibility: |
You are being asked to take part in this study because you have multiple myeloma and you have already received one or more treatment regimens.
|
| Treatment: |
The treatment in this study is divided into 4 parts
-Induction chemotherapy and stem cell collection
-Transplant phase – Two transplants 3 to 4 months apart
-Consolidation chemotherapy with DPACE
-Maintenance therapy
|
| Contact: |
Nathan Petty, e-mail: pettynathanm@uams.edu
Phone: 501-526-6990 ext 2435
|
